Chanelle Pharma

What Chanelle Pharma does

Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer of both medical and veterinary products, founded in 1985 by veterinary surgeon Michael Burke and headquartered on an 18-acre campus in Loughrea, Co. Galway. The company develops, registers, manufactures, and out-licenses generic human and animal health pharmaceutical products, holding over 4,500 product licenses worldwide — including 3,000+ animal health licenses (described as the largest number of registered veterinary licenses of any company in the EU) and 1,200+ human health licenses. Operations span three manufacturing facilities in Ireland plus an R&D laboratory in Jordan (established 2008), with sales and marketing offices in the UK and Portugal, serving customers in approximately 96 countries across the EU, Canada, Asia, Australia, and the Middle East.

The company's core technology stack centers on integrated generic pharmaceutical development capabilities — product synthesis, formulation development, process validation, stability studies, bioequivalence studies, and regulatory dossier preparation — executed by 70+ scientists across five R&D laboratories. Manufacturing capabilities span tablets, capsules, organic liquids, powders and granules, coatings, and aqueous liquids, with specialization in anthelmintics, antibiotics, sedatives, NSAIDs, cardiovascular drugs, ectoparasiticides, and anti-epileptic drugs. In March 2026, Chanelle announced a strategic partnership with SAP to implement SAP S/4HANA Cloud (private edition) and SAP Business AI, targeting a late-2026 go-live for digital transformation of CDMO operations.

The business model is B2B sales-led, combining direct enterprise sales to major and indigenous generic pharmaceutical companies, out-licensing of dossiers to leading human generic and animal health multinationals (the company supplies 10 of the top 12 multinational animal health companies), contract development and manufacturing organization (CDMO) services, and a distributor/agent channel for Chanelle-branded veterinary products outside the EU. Animal Health was ranked 14th in Europe and 38th globally by S&P Global for fiscal 2023. Following the February 2024 acquisition by European private equity firm Exponent, the company installed a new senior leadership team (Angelo Gatto as first non-family CEO), expanded its Board of Directors with global animal health and manufacturing executives, restructured into two dedicated Animal Health and Human Pharma divisions, and is pursuing headcount growth (from approximately 550 to over 700 employees) supported by a domestic recruitment partnership with ICE Group.

Name

Chanelle Pharma

Legal name

Chanelle Pharma Unlimited

Website

https://chanellepharma.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer, developing, registering, manufacturing, and out-licensing human and veterinary generic medicines to multinational pharmaceutical companies across 96 countries, with over 4,500 product licenses and 700+ employees.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Generic pharmaceuticals
• Veterinary medicines
• Animal health products
• Contract manufacturing
• Pharmaceutical development

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Products: Development, registration, manufacturing and out-licensing of generic human pharmaceutical products. Products commercialised under labels of leading pharmaceutical companies worldwide.
2. Veterinary Pharmaceutical Products: Development, registration, manufacturing and out-licensing of generic veterinary pharmaceutical products with diverse portfolio of large and small animal products supplying global market.
3. Dossier and Finished Product Sales: Sale of generic and OTC dossiers and finished products to major and indigenous generic pharmaceutical companies.
4. Contract Manufacturing Services: Contract development and manufacturing services for pharmaceutical companies with world-class manufacturing environment and ample capacity.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer, developing, registering, and producing generic human medicines and a broad range of veterinary medicines for both companion and production animals. The company also offers integrated contract development and manufacturing services (CDMO) to other pharmaceutical companies, leveraging its in-house R&D labs and multi-format production facilities across Ireland, the UK, Portugal, and Jordan.

Product overview

Chanelle Pharma operates as a fully integrated pharmaceutical company offering both human and animal health generic products and contract manufacturing services. The human health division provides generic pharmaceuticals across therapeutic areas including CNS, Cox-2 Inhibitors, Antihistamines, Cardio/anti-hypertensive, Dermatology, Diabetes, and Osteoporosis. The animal health division offers an extensive portfolio of veterinary products including anthelmintics (Albex®, Animec®, Tribex®, Moxodex®, Bovex®), anaesthetics and sedatives (Bupaq®, Butador®, Chanazine®), NSAIDs (Canidryl®, Rheumocam®), antibiotics (Clinacin®, Fenoflox®, Milbotyl®), antiparasiticides (Fipnil®, Fleaway®, Prazitel®), and nutritional supplements (Chanatol®, Thrive Extra®). Beyond product sales, Chanelle Pharma provides comprehensive contract development and manufacturing organization (CDMO) services including R&D, formulation development, process validation, stability studies, bioequivalence studies, regulatory affairs support, and product packaging. The company serves B2B customers, distributors, and wholesale markets across approximately 90-100 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Albex: Anthelmintic product brand for cattle and sheep
• Moxodex
• Tribex
• Animec
• Bovex
• Rheumocam
• Canidryl
• Chanatol
• Fipnil

Products and services

• Human Health Generic Pharmaceuticals Portfolio of generic human pharmaceutical products developed and manufactured by Chanelle for distribution to multinational pharmaceutical companies and global procurement customers. Includes finished dosage forms across multiple therapeutic categories.
• Animal Health Veterinary Product Portfolio Broad branded veterinary medicine portfolio covering both companion (small) and production (large) animals, including brands such as Albex, Animec, Flimabo, Biodectin, Ectoline, Zerotal, Iver, Fenoflox, Closamectin, and Cydectin. Sold to animal health companies, distributors, and veterinary wholesalers worldwide.
• Contract Development and Manufacturing Services (CDMO) Integrated contract development and manufacturing services for human and animal health pharma clients, drawing on Chanelle's 70+ scientist R&D team and multi-format manufacturing capabilities (tablets, capsules, liquids, creams, ointments, sterile and non-sterile liquids, powders, granules, injectable vials).

Quantifiable outcome

• Over 4,500 licenses registered in countries worldwide
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• Galway RacecourseflagshipGTM or Marketing Partner · 1 June 202641-year sponsorship partnership for Leading Trainer Award and Best Turned Out Series at Galway Races Summer Festival. One of the longest-running sponsorships in Irish racing.
• SAPcoreTechnology or Integration · 1 March 2026Strategic partnership to implement SAP S/4HANA Cloud (private edition) and SAP Business AI. Major investment in digital transformation for operational excellence with targeted go-live of late 2026.
• TenthpincoreImplementation/ SI/ Consulting Partner · 1 March 2026Partner for SAP implementation using sophisticated SAP Signavio processes optimized for Contract Development and Manufacturing Organisations (CDMOs).
• KaarTechcoreImplementation/ SI/ Consulting Partner · 1 March 2026Joint implementation partner for SAP S/4HANA Cloud transformation project.
• ICE GroupminorOthers · 1 January 2024Domestic recruitment partnership for Irish workforce expansion. ICE Group currently employs more than 700 people in Ireland.

Scale indicators13 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Perrigo Company: Large global generic pharmaceutical manufacturer with a strong OTC and prescription generics franchise plus an animal health presence. Comparable as a broad incumbent in generic human and consumer health manufacturing where Chanelle's generic dossier/finished dose business competes.

Direct peers

• Vetoquinol: Independent French animal health pharmaceutical group offering generic and branded veterinary medicines across companion animal and livestock. Direct peer given its integrated R&D, manufacturing and global commercial model in animal health generics.
• Huvepharma: Bulgarian-headquartered global animal health and nutrition company with vertically integrated manufacturing of veterinary pharmaceuticals, vaccines and feed additives. Comparable given its generic-leaning animal health portfolio and global export model similar to Chanelle's.
• Ceva Santé Animale: Global veterinary pharmaceutical company headquartered in France, focused on companion animal, poultry, swine and ruminant pharmaceuticals and vaccines. Comparable to Chanelle in integrated development, manufacturing and worldwide distribution of veterinary generics and branded products.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company focused on companion animal endocrinology, NSAIDs, antibiotics and dermatology. Highly comparable in veterinary pharmaceutical development, regulatory expertise and global distribution to vets and animal health distributors.
• Aenova Group: One of Europe's largest contract development and manufacturing organizations (CDMOs) for human pharmaceuticals, producing solid, semi-solid and liquid dosage forms. Closely comparable to Chanelle's CDMO offering (and a previous employer of Chanelle's CEO), serving major pharma companies with formulation, manufacturing and regulatory services.
• Norbrook Laboratories: UK/Ireland-headquartered generic veterinary pharmaceutical manufacturer with a globally distributed animal health portfolio of anti-infectives, anti-inflammatories and parasiticides. Direct comparable to Chanelle given similar geographic origin, generic vet focus, and CDMO-style offerings for global animal health companies.
• Adragos Pharma: European CDMO focused on solid oral dosage forms with sites in Germany, France and elsewhere. Highly comparable to Chanelle's contract manufacturing arm and to the CDMO capabilities being built out under Exponent's ownership.

Emerging players

• Alivira Animal Health: India-based animal health pharmaceutical company with a global generics portfolio across livestock and companion animals. Comparable as a low-cost emerging competitor in the same veterinary generic categories (anthelmintics, antibiotics, NSAIDs) where Chanelle operates.
• Putney Inc. US-based generic veterinary pharmaceutical company that was acquired for $200 million and whose founder now sits on Chanelle's board. Direct comparable in the US generic vet pharma space and a useful benchmark for what a focused generic animal health platform can be valued at on exit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Chanelle_Pharma
• YouTubeyoutube.com/channel/chanelle
• Facebookfacebook.com/chanellepharma
• LinkedInlinkedin.com/company/chanelle

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles35 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chanelle Pharma